Literature DB >> 6863580

Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.

T S Foster, S R Hamann, V R Richards, P J Bryant, D A Graves, R G McAllister.   

Abstract

Nifedipine kinetics have not been described in clinically relevant detail because of difficulties in formulating a stable preparation for intravenous use and lack of a specific and sensitive assay for plasma nifedipine. We recently developed a gas-chromatographic method and determined conditions in which nifedipine could be protected from photodegradation. Therefore, we evaluated the kinetics and bioavailability of nifedipine in 12 normal subjects after single intravenous (1 mg/5 min) and oral (10 mg) doses. After intravenous dosing, the drug was eliminated with a half-time of 1.77 +/- 0.25 hour, and total clearance was calculated at 0.62 +/- 0.09 liter/kg/hr. With oral drug administration, the elimination half-time was twice as long for the group; but within these subjects, marked variability in the rate of appearance of the drug in plasma was observed, giving profiles consistent with fast and slow absorption. In the latter group, peak plasma drug concentrations were only one third the level seen in those exhibiting a faster absorption profile, although the extent of drug absorption (as derived from areas under the plasma level-time curves) did not vary. Bioavailability was 0.45 +/- 0.08. Untoward effects resulting from the drug's pharmaco-subjects after intravenous administration (flushing).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6863580     DOI: 10.1002/j.1552-4604.1983.tb02720.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  50 in total

1.  Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients.

Authors:  K Schönholzer; C Marone
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pharmacokinetics of nifedipine derived from a new retard tablet formulation.

Authors:  A Avgerinos; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

3.  Ethnic differences in the pharmacokinetics of oral nifedipine.

Authors:  C H Ahsan; A G Renwick; B Macklin; V F Challenor; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

Review 4.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

5.  Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women.

Authors:  Gabriela Campos de Oliveira Filgueira; Osmany Alberto Silva Filgueira; Daniela Miarelli Carvalho; Maria Paula Marques; Elaine Christine Dantas Moisés; Geraldo Duarte; Vera Lucia Lanchote; Ricardo Carvalho Cavalli
Journal:  Br J Clin Pharmacol       Date:  2017-01-29       Impact factor: 4.335

6.  A defence of the small clinical trial: evaluation of three gastroenterological studies.

Authors:  J Powell-Tuck; K D MacRae; M J Healy; J E Lennard-Jones; R A Parkins
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

7.  Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.

Authors:  D R Robertson; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

8.  Haemodialysis does not affect the pharmacokinetics of nifedipine.

Authors:  H Martre; R Sari; A M Taburet; C Jacobs; E Singlas
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

9.  Nifedipine: kinetics and dynamics after single oral doses.

Authors:  H R Ochs; K D Rämsch; B Verburg-Ochs; D J Greenblatt; J Gerloff
Journal:  Klin Wochenschr       Date:  1984-05-02

10.  Correlation between the plasma concentration of mepirodipine and its occupancy of Ca2+ antagonist receptors in rats.

Authors:  S Yamada; Y Matsuoka; R Kimura
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.